Human lives
drive our discovery
of microbiome therapeutics

Finch is a clinical-stage microbiome therapeutics company

leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.

Human-First Discovery platform

Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.

Learn more


We are developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with a candidate in late-stage clinical development for recurrent C. difficile, and candidates for inflammatory bowel disease, autism spectrum disorder, and chronic hepatitis B in pre-clinical development.

Learn more

Recent news

Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder

January 06, 2022

Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

January 04, 2022

Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

December 20, 2021

Join us

Join us in our mission to transform the lives of patients and families fighting serious medical conditions.

Learn more